PubMed Health⌕ Search

Biomedical subjects

F Mora

Publications and source records attributed to F Mora.

At least 73 records · Page 4Linked to original sources

Bartter syndrome in Costa Rica: a description of 20 cases.

Bartter syndrome involves an overlapping set of closely related renal tubular disorders which can be subdivided into at least three clinical phenotypes: (1) classic Bartter syndrome (2) Gitelman syndrome, and (3) a neonatal variant of Bartter syndrome. In contrast to classic Bartter syndrome and Gitelman syndrome, the neonatal variant of Bartter syndrome has both the features of renal tubular hypokalemic alkalosis as well as profound systemic manifestations. Specifically, neonatal Bartter syndrome is characterized by intrauterine polyhydramnios, premature delivery, and life-threatening episodes of fever and dehydration. Most of these infants also have severe hypercalciuria with associated nephrocalcinosis and osteopenia. Over a 22-year period, 20 Costa Rican patients with a congenital syndrome that resembles neonatal Bartter syndrome have been identified and characterized. While these patients exhibit some of the clinical characteristics previously described for neonatal Bartter syndrome, this cohort also has a set of distinct features. They are predominantly female, have a later age of diagnosis, manifest a relatively unique set of physical traits, and appear to have milder clinical disease. Given these differences, it will be important to apply the emerging molecular tools to determine whether the phenotypic variability indicates genetic heterogeneity in neonatal-onset Bartter syndrome.

Age of Onset↗

M1 muscarinic receptor stimulation decreases aspartate release in the rat neostriatum.

This study investigates the effects of different muscarinic receptor agonists on extracellular glutamate and aspartate concentrations in the rat neostriatum. In vivo intracerebral perfusions were undertaken in the conscious rat using a concentric push-pull cannulae system. Amino acid concentrations in samples were determined by HPLC with fluorometric detection. The intrastriatal perfusion of arecoline, a M1-M2 muscarinic receptor agonist, produced a significant decrease in extracellular [ASP] (45% of decrease) but not in extracellular [GLU]. These effects were blocked by scopolamine, a M1-M2 muscarinic receptor antagonist. McN-A-343, a M1 muscarinic receptor agonist, but not the M2 muscarinic receptor agonist, oxotremorine, produced a significant decrease in extracellular [ASP] (40% of decrease) but not in extracellular [GLU]. The effects of McN-A-343 on extracellular [ASP] were blocked by pirenzepine, a M1 muscarinic receptor antagonist. These results suggest that the decrease in extracellular [ASP] could be mediated, at least in part, by M1 muscarinic receptor activation in the rat neostriatum.

(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethy↗

Effects of 4-aminopyridine on extracellular concentrations of glutamate in striatum of the freely moving rat.

4-aminopyridine (4-AP) is a voltage-sensitive K(+)-channel blocker extensively used in in vitro experiments as a depolarizing agent for the release of glutamate (GLU). This research investigated whether 4-AP could be used in in vivo experiments using microdialysis. For that, the effects of 4-AP on the extracellular concentrations of glutamate (GLU), glutamine (GLN), taurine (TAU) and citrulline (CIT) in striatum of the freely moving rat were investigated. The effects of 4-AP were compared with those produced by perfusion with a high K+ (100 mM) medium. Intrastriatal perfusion with 4-AP (1, 5 and 10 mM) produced no effects on extracellular [GLU], [TAU] and [CIT], but decreased extracellular [GLN]. Perfusion with a high K+ (100 mM) medium increased extracellular [GLU] and [TAU], decreased extracellular [GLN], and had no effects on [CIT]. To test whether the lack of effects of 4-AP on extracellular [GLU] was due to GLU uptake mechanisms, 4-AP was perfused after a previous inhibition of GLU uptake with L-trans-pyrrolidine-2,4-dicarboxylic acid (PDC). Under the effects of PDC (1 mM), 4-AP (1 mM) had no effects on extracellular [GLU], [TAU] and [CIT], but decreased extracellular [GLN]. These results show that 4-AP decreased extracellular [GLN] but failed to produce a significant release of GLU in striatum of the freely moving rat. Thus, 4-AP can not be used as a depolarizing agent for stimulating the release of GLU in in vivo studies using microdialysis.

4-Aminopyridine↗

M1 acetylcholine receptor stimulation increases the extracellular concentrations of glutamate and GABA in the medial prefrontal cortex of the rat.

The present study was undertaken to examine the effects of different muscarinic receptor agonists on glutamate and GABA concentrations in the medial prefrontal cortex of the rat. In vivo perfusions were made in the conscious rat using a concentric push-pull cannulae system. Amino acid concentrations in samples were determined by HPLC with fluorometric detection. The intracortical perfusion of arecoline, a M1-M2 muscarinic receptor agonist, produced a significant increase in extracellular [GLU] and [GABA]. McN-A-343, a M1 muscarinic receptor agonist, but not the M2 muscarinic receptor agonist, oxotremorine, produced a significant increase in extracellular [GLU] and [GABA]. The effects of McN-A-343 on extracellular [GLU] and [GABA] were blocked by pirenzepine, a M1 muscarinic receptor antagonist. These results suggest that M1 muscarinic receptor stimulation increases the extracellular concentrations of GLU and GABA in the medial prefrontal cortex of the rat.

(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethy↗

Endogenous glutamate increases extracellular concentrations of dopamine, GABA, and taurine through NMDA and AMPA/kainate receptors in striatum of the freely moving rat: a microdialysis study.

Interactions between glutamate (Glu), dopamine (DA), GABA, and taurine (Tau) were investigated in striatum of the freely moving rat by using microdialysis. Intrastriatal infusions of the selective Glu uptake inhibitor L-trans-pyrrolidine-3,4-dicarboxylic acid (PDC) were used to increase the endogenous extracellular [Glu]. Correlations between extracellular [Glu] and extracellular [DA], [GABA], and [Tau], and the effects of a selective blockade of ionotropic Glu receptors, were studied. PDC (1, 2, and 4 mM) produced a dose-related increase in extracellular [Glu]. At the highest dose of PDC, [Glu] increased from 1.55 +/- 0.35 to 6.11 +/- 0.88 microM. PDC also increased extracellular [DA], [GABA], and [Tau]. The increasing [Glu] was correlated significantly with increasing [DA], [GABA], and [Tau]. PDC also decreased extracellular concentrations of DA metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and 4-hydroxy-3-methoxyphenylacetic acid (HVA). Perfusion with the NMDA-receptor antagonist 3-[(R)-2-carboxypiperazin-4-yl]-propyl-1-phosphonic acid (1 mM) or the AMPA/kainate-receptor antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX) (1 mM) attenuated the increases produced by PDC (4 mM) on [DA], [GABA], and [Tau], and decreases in [DOPAC] and [HVA]. DNQX also attenuated the increases in [Glu] induced by PDC. These data show that endogenous Glu plays a role in modulating the extracellular concentrations of DA, GABA, and Tau in striatum of the freely moving rat.

Animals↗

Treatment of interproximal angular defects by guided tissue regeneration: 1 year follow-up.

The periodontal regeneration of interproximal bone defects of the posterior teeth produced by guided tissue regeneration (GTR), with expanded Polytetrafluoroethylene barrier membranes and conventional therapy, was clinically evaluated in 20 intrabony periodontal defects in 10 patients. The material included the presence of at least two proximal angular lesions for the same patient, probing pocket depth > or = 6 mm, bone defect depth > or = 3 mm, and 2-wall defects with crestal involvement relative to the tooth circumference ranging from 90 to 270 degrees. Healing was clinically evaluated by surgical re-entry of GTR-treated sites (10 sites) and debridement only sites (10 sites) 1 year after initial surgery following a strict plaque control regimen. A significant correlation was observed between probing depth reduction, attachment gain and defect depth (test sites); there was increased bone fill in GTR-treated lesions of 2.95 +/- 1.3 mm corresponding to a 69.4% improvement compared to control sites, and 1.3 +/- 1.0 mm corresponding to a 32% improvement (P < 0.0039). The results demonstrated that bone regeneration is highly reliable, as compared to conventional therapy, in cases of severe periodontal bone loss from posterior teeth provided that the principles of GTR are applied.

Adult↗

Laparoscopic treatment of esophageal achalasia.

An observational cohort study evaluated the initial results of using laparoscopic-approach cardioesophageal myotomy with Dor-type anterior fundoplicature for esophageal achalasia. The study involved our first 12 patients: five men and seven women whose median age was 51 years. Esophageal motility was vigorous in four patients; the other eight had aperistalsis. Conversion to laparotomy was required in one case. No postoperative mortality occurred. Postoperative complications included one left subdiaphragmatic abscess secondary to perforation of the esophageal mucosa, which was sutured. Median postoperative hospital stay was 5 days (confidence interval, 4.7-6.7 days). Symptom relief (disappearance of dysphagia) was recorded in 10 cases; relief with partial persistence of dysphagia was observed in the remaining two patients, who were treated by postoperative dilatation. As to the postoperative manometric results, the median basal pressure of the lower esophageal sphincter was reduced from 26.3 mm Hg preoperatively to 15.5 mm Hg postoperatively, with a tendency toward statistical significance (p = 0.08); the median esophageal isotopic retention after 15 min decreased from 60% preoperatively to 24.5% after surgery, with a tendency toward statistical significance (p = 0.07). Cardiomyotomy with Dor fundoplicature through a laparoscopic approach seems effective in treating esophageal achalasia.

Esophageal Achalasia↗

The modulatory effect of melatonin on the dopamine-glutamate interaction in the anterior hypothalamus during ageing.

We investigated the effects of melatonin on the dopamine-glutamate interaction in the anterior hypothalamus of young, middle-aged and aged rats. In young rats, under the effects of amphetamine, melatonin produced an inhibition of dopamine release and a significant increase in glutamate and aspartate release. In middle-aged and aged rats, the inhibitory effects of melatonin on amphetamine-evoked dopamine release were maintained, but no effects on glutamate or aspartate release were found. These results suggest that, during ageing, the modulatory effect of melatonin on dopamine release in rat anterior hypothalamus is preserved whereas the dopamine-glutamate interaction is disrupted with age.

Aging↗

Dopamine--glutamate--GABA interactions and ageing: studies in the striatum of the conscious rat.

The effects of apomorphine, a D1-D2 dopamine receptor agonist, on the extracellular concentrations of glutamate and GABA were investigated in the striatum of young, middle-aged and aged rats. In vivo intracerebral perfusions were undertaken in the conscious rat using a concentric push-pull cannula system. Amino acid concentrations in samples were determined by HPLC with fluorometric detection. Apomorphine produced a concentration-related rise in striatal glutamate and GABA concentrations in young rats. Maximal increases were obtained at 20 microM apomorphine, and concentrations reached 184 and 191% of the basal value for glutamate and GABA respectively. Apomorphine failed to produce similar increases in glutamate concentration in middle-aged and aged rats. Apomorphine, at 10 microM, also failed to produce an increase in GABA concentration in the aged rats. However, at 20 microM apomorphine produced increases in GABA concentration in middle-aged and aged rats similar to those produced in young rats. These data are indicative of a change in threshold for GABA release induced by dopamine receptor stimulation in the aged rat. These results indicate that an interaction among dopamine, glutamate and GABA exists in the striatum of the rat, and that this type of interaction deteriorates with age.

Aging↗

Dopamine-glutamic acid interaction in the anterior hypothalamus: modulatory effect of melatonin.

The aim of the present study was to investigate the role of melatonin as neuromodulator. For that, the effects of melatonin on the extracellular concentrations of excitatory amino acids, glutamic and aspartic acids, were investigated in the anterior hypothalamus and parieto-temporal cortex of the conscious rat using an intracerebral perfusion system. Melatonin at doses of 250 nM and 1 microM produced no effects on extracellular glutamate and aspartate concentrations in these two areas of the brain. Since amphetamine releases dopamine we perfused melatonin into the anterior hypothalamus and parieto-temporal cortex after a previous injection of amphetamine. Interestingly, we found a release of glutamic acid (p < 0.01) and aspartic acid (p < 0.01) produced by melatonin only when the increase (157%) of the extracellular dopamine concentration evoked by amphetamine was inhibited by melatonin in the anterior hypothalamus. The possibility is discussed of melatonin exerting its effects when the dopaminergic system is activated.

Animals↗

An approach to intelligent ischaemia monitoring.

The paper describes an approach to intelligent ischaemia event detection based on ECG ST-T segment analysis. ST-T trends are processed by means of a Bayesian forecasting approach using the multistate Kalman filter. A complete procedure, intended for use in CCU/ICU monitoring areas, is proposed, in order to give the clinician an intelligent monitoring tool. The approach serves to describe trends and their changes in a symbolic way. A novel aspect is its ability to observe certain features of ST-T elevation/depression not detected by other means, and to reject artefacts and erroneous events. A sensitivity of 89.58% and a predictivity of 84.31% are obtained on selected records of the European ST-T database. Using a restriction on event amplitude, the predictivity is raised to 95.55%. An ischaemia sensitivity index of 1.2 was determined. The method has been shown to be a robust and practical trend analysis tool, and seems to be appropriate for numeric/symbolic transformations in next-generation intelligent monitoring systems.

Bayes Theorem↗

Glucagon-like peptide-1(7-36)amide induces the release of aspartic acid and glutamine by the ventromedial hypothalamus of the conscious rat.

Glucagon-like peptide-1(7-36)amide (GLP-1(7-36)amide) and its own receptor have been found in the hypothalamus and brain stem of the rat. In an attempt to gain further insight into the role of this peptide in brain functioning we investigated the effects of GLP-1 (7-36)amide on the release of excitatory amino acid neurotransmitters by the ventromedial hypothalamus using an experimental microdialysis approach. GLP-1(7-36)amide produced an immediate increase in the extracellular concentrations of aspartic acid and glutamine, p < 0.01 and p < 0.05, respectively. By contrast, extracellular concentrations of glutamic acid, alanine, threonine, and tyrosine were unaffected. The results of this study show a stimulatory effect of GLP-1(7-36)amide on the release of aspartic acid and glutamine by the ventromedial hypothalamus of the rat.

Animals↗

Structural characterization by affinity cross-linking of glucagon-like peptide-1(7-36)amide receptor in rat brain.

Specific binding of glucagon-like peptide (GLP)-1(7-36)amide was detected in several rat brain areas, with the highest values being found in hypothalamic nuclei and the nucleus of the solitary tract. In hypothalamus and brainstem homogenate binding of 125I-GLP-1(7-36)amide was time, temperature, and protein content dependent and was inhibited by unlabeled proglucagon-derived peptides. The rank order of potency was GLP-1(7-36)amide >> GLP-1(1-36)amide > GLP-1(1-37) approximately equal to GLP-2 > glucagon. Scatchard analysis of the steady-state binding data was consistent with the presence of both high- and low-affinity binding sites in hypothalamus and brainstem. Brain 125I-GLP-1(7-36)amide-binding protein complexes were covalently cross-linked using disuccinimidyl suberate and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. A single radiolabeled band of M(r) 56,000 identified in both hypothalamus and brainstem homogenates was unaffected by reducing agents. An excess of unlabeled GLP-1(7-36)amide abolished the band labeling, whereas glucagon had no effect. Other unlabeled GLPs inhibited M(r) 56,000 complex labeling with the following order of potency: GLP-1(1-36)amide > GLP-1(1-37) > GLP-2. The binding of 125I-GLP-1(7-36)amide and the intensity of the cross-linked band were similarly inhibited in a dose-response manner by increasing concentrations of unlabeled GLP-1(7-36)amide. Covalent M(r) 56,000 125I-GLP-1(7-36)amide-binding protein complexes solubilized by Triton X-100 were adsorbed onto wheat germ agglutinin.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

Dopamine receptor blockade inhibits the amphetamine-induced release of diadenosine polyphosphates, diadenosine tetraphosphate and diadenosine pentaphosphate, from neostriatum of the conscious rat.

The diadenosine polyphosphates diadenosine tetraphosphate (Ap4A) and diadenosine pentaphosphate (Ap5A) are costored with ATP and released in a calcium-dependent manner from neural preparations in vitro. By means of a push-pull perfusion system, samples from conscious rat were collected from the caudate putamen area, and nucleotide compounds were analyzed by HPLC. The adenine dinucleotides were not detectable before systemic amphetamine injection. The maximal levels were reached 20 min after injection, independently of the dose. The EC50 values for amphetamine-induced release of dinucleotides were 2.04 +/- 0.15 and 2.43 +/- 0.36 mg/kg for Ap4A and Ap5A, respectively. Amphetamine doses higher than 5 mg/kg did not increase the dinucleotide release, the maximal values being 12.9 +/- 0.9 and 11.5 +/- 0.9 pmol/fraction for Ap4A and Ap5A, respectively, which corresponds with 64.5 and 57.5 nM in the samples. Adenosine and AMP were present in push-pull samples from rat brain under basal conditions. Their levels were 15 pmol/fraction (75 nM) and 50 pmol/fraction (250 nM) for adenosine and AMP, respectively. A significant increase was obtained for both compounds after amphetamine injection. The adenosine increase reached 45 pmol/sample (225 nM), which was 200% of the basal value 20 min after the stimulant administration. The increase at other times was not significant. The AMP levels increased significantly from 10 to 50 min. The maximal level was reached 20 min after amphetamine injection, with 150 pmol/fraction (750 nM), which represents a 200% increase with respect to the basal level. The adenine dinucleotide release was blocked by the dopamine receptor antagonist haloperidol, which returned the levels to the control basal values.(ABSTRACT TRUNCATED AT 250 WORDS)

Adenosine↗

Clinical evaluation of natural coral and porous hydroxyapatite implants in periodontal bone lesions: results of a 1-year follow-up.

This study examines the suitability of 2 bone graft substitutes, natural coral skeleton (NCS) and porous hydroxyapatite (PHA) for treating periodontal bone defects in human subjects, and compares them to debridement alone (DEBR). A total of 30 sites in 10 patients were treated. Measurements were made before treatment and during surgical reexamination 12 months after treatment on lesions filled with NCS (10 sites), PHA (10 sites), or DEBR (10 sites). There was no significant difference in the use of NCS or PHA for 1, 2 wall, or combined defects for the group of parameters measured in this study (clinical probing depth, clinical attachment, gingival recession, bone fill, % bone fill, and crest remodelling). Statistical analysis (Wilcoxon non-parametric test for paired values and ANOVA for repeated measurements) revealed the beneficial effects of using each the biomaterials (57.4% for NCS, 58.1% for PHA, p < 0.86) as opposed to simple debridement (22.2%; p < 0.002; p < 0.004).

Adult↗

Effects of a nitric oxide donor on glutamate and GABA release in striatum and hippocampus of the conscious rat.

The effects of intracerebral perfusion of the nitric oxide (NO) donor 3-morpholino-sydnonimine (SIN-1) and the nitric oxide synthase inhibitor N-nitroarginine (NARG) on the extracellular concentrations of glutamate (GLU) and gamma-aminobutyric acid (GABA) in striatum and CA1 area of the hippocampus were studied. Continuous push-pull perfusions at a flow rate of 20 microliters min-1 were performed in the conscious rat. SIN-1 (100, 200, and 400 microM) and NARG (100 microM) were perfused over 20 min. In both striatum and CA1 SIN-1 increased extracellular concentrations of GLU (maximal increase 150% and 197% of baseline, respectively) and GABA (maximal increase 202% and 204% of baseline, respectively). NARG had no effects on extracellular levels of GLU and GABA in either area. These results are consistent with the hypothesis that NO acts as a modulator of GLU and GABA release in both striatum and hippocampus. This study is the first to report the potentiation of GLU and GABA release by NO in CA1 area of the hippocampus in the conscious rat.

Amino Acid Oxidoreductases↗

Effects of apomorphine and L-methionine sulphoximine on the release of excitatory amino acid neurotransmitters and glutamine in the striatum of the conscious rat.

The effects of apomorphine, a D1-, D2-dopamine receptor agonist, on the extracellular concentrations of excitatory amino acids, glutamic and aspartic acids, and on that of their precursor, glutamine, were investigated using an intracerebral perfusion system. Apomorphine produced a concentration-related rise in glutamic acid concentration in cerebral perfusates (P < 0.01) whereas only the highest concentration of apomorphine (3 x 10(-3) micrograms/microliters) increased the concentration of aspartic acid (P < 0.05). These effects were seen in the sample taken at the same time as the apomorphine injection. The rise in glutamine concentration (P < 0.01) produced by apomorphine continued for 10 min beyond perfusion with apomorphine. These effects were attenuated by previous injections of D1-, D2-dopamine receptor blocker. To investigate further the release of glutamine, the glutamine synthetase inhibitor L-methionine sulphoximine (MSO) was injected intracerebrally before apomorphine perfusion. After MSO pre-injection, the extracellular concentration of glutamine decreased (P < 0.01) to near zero concentrations. In MSO-treated animals, apomorphine did not induce the release of glutamic acid, aspartic acid or glutamine. These results indicate a role for dopamine in the release of excitatory amino acids and glutamine in the neostriatum of the rat. A possible volumetric interaction between dopamine and glutamic acid as well as the hypothesis of a striato-pallido-thalamo-cortico-striatal feedback loop are discussed.

Analysis of Variance↗

Active microglia, sick astroglia and Alzheimer type dementias.

We propose that Alzheimer's disease is initiated by failure of axonal transport. After the neurodegeneration cascade is initiated, microglial and astroglial cells have major roles in directly and indirectly promoting self-sustaining neurodegeneration cycles. This hypothesis makes testable predictions and suggests logical therapies.

Alzheimer Disease↗